PSMA PET holds promise not only as a diagnostic but also possibly a theranostic tool in the management of advanced-stage HCC, which, despite advancements in treatment, has a median overall survival of less than 2 years [31]. The gene discussed is FOLH1; the disease is hepatocellular carcinoma.